BK1067 Pharmaceuticals
- 567.395
- -0.696-0.12%
Le Méridien Vaccine (06660.HK) received 400 additional H shares by Zhou Yan, worth approximately HK$3,328
On May 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 3, Zhou Yan increased her H shares of $Aimei Vaccine (06660.HK) by $400 at an average price of HK$8.32 per share on April 26, worth about HK$3,328. After the increase in holdings, Zhou Yan's latest shareholding was 24.5816 million shares, with a good position ratio of 4.99%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies are required
Xiansheng Pharmaceutical (02096) spent HK$781,600 to buy back 138,000 shares on May 3
According to the Zhitong Finance App, Xiansheng Pharmaceutical (02096) announced that on May 3, 2024, the company spent HK$781,600 to repurchase 138,000 shares at a repurchase price of HK$5.64-5.67 per share.
CSPC Group (01093.HK) cancelled 26.628 million shares on May 3
Gelonghui, May 3, 丨 Shiyao Group (01093.HK) announced that on May 3, 2024, 26.628 million shares have been cancelled.
CCB International: Maintaining Cinda Biotech's (01801) “Outperform the Market” rating and raising the target price to HK$54.7
According to CCB International, Cinda Biotech (01801) is one of the bank's preferred stocks in the Chinese pharmaceutical industry.
Hong Kong Stock Concept Tracking | China's Nuclear Medicine Industry Attracts Attention (with concept stocks), the key technology for batch online irradiation production of isotopes
Various short-half-life medical isotopes that are currently in short supply in China will enter the large-scale production stage after the supporting plant is completed and put into operation in the second half of this year.
Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop
Antengene's (HKG:6996) attributable loss narrowed to 581.2 million yuan, or 0.94 yuan per share, in 2023 from 601.5 million yuan, or 0.97 yuan per share, in 2022, according to the company's annual rep
PHARMARON To Go Ex-Dividend On June 27th, 2024 With 0.22051 HKD Dividend Per Share
May 2nd - $PHARMARON(03759.HK)$ is trading ex-dividend on June 27th, 2024. Shareholders of record on June 28th, 2024 will receive 0.22051 HKD dividend per share. The ex-dividend date is June 27th,
China Medical Network (00383.HK) Stock Short Name Change Effective May 7
Gelonghui, May 2, 丨 China Medical Network (00383.HK) announced that the English stock abbreviation of the company used to trade shares on the Stock Exchange will be changed from “CHINA MED&HCARE” to “TIANAN MEDICARE”, while the Chinese stock abbreviation will be changed from “China Medical Network” to “Tianandongjian”, effective from 9:00 a.m. on May 7, 2024.
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%
Sihuan Pharmaceutical Holdings Group (HKG:0460) said its New Drug Application (NDA) to China's National Medical Products Administration (NMPA) was accepted for the lung cancer drug Dexitinib tablets,
Changes in Hong Kong stocks | Cinda Biotech (01801) is now up more than 9%, and total product revenue in the first quarter has increased by more than 60%. The company will release multiple clinical data at ASCO
Cinda Biotech (01801) is now up more than 9%. As of press release, it is up 9.02% to HK$41.7, with a turnover of HK$265 million.
Sihuan Pharmaceutical (00460.HK): Xuanzhu Biotech independently developed a Class 1 innovative drug “daxitinib tablets” and applied for marketing to the State Drug Administration and accepted
On May 2, Ge Longhui Pharmaceutical (00460.HK) announced that the Class 1 innovative anti-tumor drug “daxitinib tablets” (product code: XZP-3621) independently developed by Xuanzhu Biotechnology Co., Ltd. (“Xuanzhu Biology”), a non-wholly-owned subsidiary of the Group, has been declared for marketing and accepted by China's National Drug Administration (“State Drug Administration”). The specific indications for this report are: It is suitable for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK). Dacitinib tablets submitted a marketing application for Xuanzhu Biotech and
Repurchase Collection on April 30 | Hang Seng Bank, Swire Group A, etc. bought back one after another. Of these, Hang Seng Bank spent HK$56.2511 million
According to documents disclosed by the Hong Kong Stock Exchange on May 2, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 540,000 common shares on April 30, involving an amount of HK$56.2511 million. The repurchase price per share ranged from HK$105 to HK$103.6. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 7.534 million shares, accounting for 0.394% of the number of shares issued when the ordinary resolution was passed. ② $Taikoo Shares
Golden Throat's Profit Declines 11% in 2023
Golden Throat Holdings Group (HKG:6896) recorded an 11% decline in attributable profit for 2023 to 250.2 million yuan from 281.2 million yuan in 2022, according to the company's annual report. Earning
Data reveal | What did Beishui buy in April? Bank of China sold over HK$10.5 billion and Tencent raised over HK$5.3 billion
Since July 2023, the southbound capital has maintained a net inflow for 10 consecutive months, with a cumulative net purchase of HK$408.792 billion during this period.
Alibaba Pictures expects year-on-year losses in the previous fiscal year to Yingxinda Biotech's product revenue increase by more than 60% in the first quarter｜Selected Hong Kong Stock Announcements
① Alibaba Pictures expects to turn a year-on-year loss into a profit in the previous fiscal year. What is the revenue growth rate? ② Cinda Biotech's product revenue increased by more than 60% in the first quarter. What is the overall scale?
Saisheng Pharmaceutical (06600): 10,000 share options have been exercised
Saisheng Pharmaceutical (06600) issued an announcement. On April 30, 2024, according to the initial public offering after-sales share purchase options...
華潤醫藥：公告有關於中國發行中期票據及公司債券的華潤醫藥控股截至2024年3月31日止三個月的未經審核財務業績
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
Pharmaron Beijing's Profit Rises 17% in 2023
Pharmaron Beijing (HKG:3759, SHE:300759) recorded a 17% rise in attributable profit for 2023 to 1.6 billion yuan from 1.37 billion yuan in 2022, according to the company's annual report. The drugmaker
China Holdings Kangtai (01312.HK) denies the charges in the 2024 Cayman petition
Gelonghui, April 30 | Huakong Kangtai (01312.HK) issued an announcement. As of the date of this announcement, neither the 2019 Hong Kong legal proceedings nor the 2021 Hong Kong legal proceedings had been tried. On April 29, 2024, the company received a petition from Active Gains (as petitioner) from True Cayman and Fester Global's overseas registered agents against True Cayman dated April 25, 2024, with respect to: (a) liquidation of True Cayman; (b)